Phoenicis is pursuing a precision drug candidate for rare, genetic, and inflammatory disorders. Our primary focus is on skin disorders with the potential to expand into other inflammatory disorders. One therapy is ready to enter the clinic for dystrophic epidermolysis bullosa later this year.

We also have an additional early-stage research pipeline in rare skin disorders. Our R&D team’s experience creating 15+ businesses, advancing 12+ drugs into the clinic, and involvement with 4 FDA and 3 EMA drug approvals in the last decade provides the expertise for real potential in reaching our objectives.